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Abstract
Background: To identify new and useful candidate biomarkers in head and neck squamous cell carcinoma
(HNSCC), we performed a genome-wide survey and found that Myelin and lymphocyte-associated protein (MAL)
was a gene that was markedly down-regulated in HNSCC. Hence, we investigated the mechanism of MAL silencing
and the effects of MAL on the proliferation, invasion, and apoptotic potential in HNSCC.
Results: MAL was significantly down-regulated in 91.7% of HNSCC specimens at the mRNA level as compared with
adjacent normal tissues (P = 0.0004). Moreover, the relative transcript levels of the MAL gene were remarkably
decreased by five-fold in nine HNSCC cell lines as compared with normal head and neck epithelium cells. MAL
gene expression was restored in 44%, 67%, and 89% in HNSCC cell lines treated with TSA, 5-Aza-dC, and TSA plus
5-Aza-dC, respectively. Furthermore, bisulfate-treated DNA sequencing demonstrated that the two CpG islands (that
is, M1 and M2) located in MAL promoter region were completely methylated in the HNSCC cell lines (CpG
methylated ratio was more than 90%), and only one CpG island (that is, M1) was partially methylated in HNSCC
tissues (CpG methylated ratio between 20% and 90%). A significant reduction in cell proliferation and a change in
the cell cycle profile were also observed in MAL transfectants. Matrigel assay demonstrated that the invasiveness of
HNSCC cells significantly decreased. A significant increase in the population of apoptotic cells was observed in MAL
transfected cells. The exogenous expression of the MAL gene suppressed malignant phenotypes, while the cell
death induced by MAL gene transfer was a result of apoptosis as demonstrated by the induction of cleavage of
the poly (that is, ADP-ribose) polymerase. Additionally, tumor growth was suppressed in cells expressing MAL as
compared with cells not expressing MAL.
Conclusion: Our data suggest that the epigenetic inactivation of MAL, as a candidate tumor suppressor gene, can
contribute to human epithelial cell carcinoma and may be served as a biomarker in HNSCC.
Background
Head and neck squamous cell carcinoma (HNSCC),
which is a type of epithelial carcinoma, is the sixth most
common cancer in the world [1]. However, surgery,
radiotherapy, and chemotherapy have not sufficiently
improved the five-year survival rate of patients with
these devastating diseases in more than three decades.
Despite ongoing efforts, no biomarkers have been identi-
fied yet. To search for useful biomarkers for the
diagnosis, therapy, and prognosis of HNSCCs, high-
throughput microarray analysis was used to identify
genes that are differentially expressed in tumors [2-6].
In a previous study [7], we used an oligonucleotide
microarray (Affymetrix HG-U95Av2) to select differen-
tially expressed genes in 22 pairs of HNSCC and normal
epithelial tissue from the same donors. Remarkably, the
Myelin and lymphocyte-associated protein gene (MAL),
which is located on chromosome 2q, was down-
regulated in HNSCC. The previous reports also
described the similar down-modulation of MAL gene
expression in certain cancer types [8-13], indicating
MAL gene downregulation might be as a common
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gression of cancers. Based on this hypothesis, MAL was
chosen for further investigation.
The MAL gene was originally identified by Alonso and
Weissman during a search for differentially expressed
genes in T-cell development [14]. The MAL protein,
which is encoded by MAL, is also to be a vesicle integral
protein. It has a molecular weight of approximately
17 kDa (VIP17) and is present in Schwann cells, in oli-
godendrocytes, and in the epithelial cells of the kidney,
stomach, and large intestine [15]. It spans the mem-
brane four times and is structurally similar to members
of the tetraspan family. In every cell in which it is
expressed, MAL is associated with glycosphingolipids; it
is also thought to be involved in the organization, trans-
port, and maintenance of glycosphingolipid-enriched
membranes, which are resistant to detergent extraction.
Because these glycosphingolipid-enriched membranes
are thought to be part of apical transport machinery
[16], MAL as a proteolipid protein is involved in normal
apical transport and accurate sorting in Madin-Darby
canine kidney cells [17,18]. The recent data on MAL
g e n ed o w n - r e g u l a t i o ni np r i m a r yh u m a ne p i t h e l i a l
malignancies suggest that the loss of the MAL gene may
be closely linked with a variety of human epithelial
malignancies [8,19,20]. Moreover, Beder et al reported
that MAL gene mRNA is downregulated in metastatic
HNSCC tumors as compared to that in primary
HNSCC tumors, implying that the decreasing MAL
expression could contribute to metastatic potential of
HNSCC [21]. The use of the MAL protein as a predic-
tive biomarker to benefit for patients undergoing che-
motherapy was also statistically analyzed in breast and
ovarian cancers [11,22]. However, the molecular
mechanism by which of MAL gene downregulation and
contribution in HNSCC initiation or progression remain
unclear. Moreover, whether MAL gene might be a valu-
able diagnostic or therapeutic biomarker for HNSCC
need to be further investigated.
In this study, we examined the expression of MAL tran-
scripts in HNSCC samples, adjacent normal epithelial tis-
sues and HNSCC cell lines using real-time RT-PCR and
semi-quantitative RT-PCR. We found that full-length iso-
form a is the only transcript variant in head and neck
epithelium; MAL transcript levels are down-regulated in
HNSCC tissues and HNSCC cell lines as compared with
adjacent normal tissues. Next, we investigated the
mechanism of MAL gene down-regulation. The aberrant
epigenetic alteration contributes to the silencing of the
MAL gene in HNSCC. Furthermore, to assess the func-
tional role of MAL in HNSCC, we evaluated the effect of
ectopic MAL expression on Tca cells, Tca-M and Tb
cells, which are HNSCC-derived cell lines. Our results
show that exogenous expression of MAL in HNSCC cell
lines inhibited the proliferation, invasion, and induced
apoptosis of cancer cells in vitro and tumorigenicity in
vivo.
Results
Identification and expression of MAL transcript shows
variations in head and neck squamous epithelium
Alonso et al [23] previously reported that sequence ana-
lysis of the human T-cell-specific MAL gene revealed
four exons, each encoding a hydrophobic, presumably
membrane-associated, segment and its adjacent hydro-
philic sequence. Alternative splicing produces four tran-
script variants, which vary by the presence or absence of
alternatively spliced exons 2 and 3. To determine
whether alternatively spliced isoforms of MAL were
expressed in head and neck squamous epithelium, a pair
of PCR-primers spanning exon 1 and exon 4 was
designed to discriminate the transcript levels of the four
variants using semi-quantitative RT-PCR analysis (Figure
1A, 1B). Our results showed that the variant a, which is
the longest of the isoforms is the only transcript variant
in head and neck squamous epithelium.
MAL is frequently down-regulated in HNSCCs and
cell lines
As our microarray data indicated, MAL expression was
reduced remarkably in HNSCC as compared to adjacent
normal tissues. To investigate whether MAL contributes to
HNSCC progression, real-time RT-PCR and semi-quantita-
tive RT-PCR analyses were performed to investigate
mRNA levels of MAL in 48 HNSCC specimens. Out of the
48 cases examined, 44 (91.7%) HNSCC specimens had at
least a two-fold decrease in MAL mRNA levels as com-
pared to non-tumorous tissues (P < 0.01, Figure 2A, 2B).
Meanwhile, the expression levels of MAL mRNA in a
panel of nine HNSCC cell lines and the immortalized oral
keratinocyte line HIOEC were detected during semi-quan-
titative RT-PCR analysis. As shown in Figure 2C, MAL
transcript levels in the HNSCC cell lines and HIOEC
cells were significantly lower than in the case of normal
epithelial cells (P <0 . 0 1 ) .
The transcription of MAL is associated with promoter
methylation in HNSCCs
Increasing evidence has shown that epigenetic silencing
of tumor suppressor genes because of aberrant DNA
hypermethylation and histone modification is essential
to carcinogenesis and metastasis [20,24]. To verify
whether MAL gene promoter hypermethylation contrib-
uted to MAL down-regulation, nine HNSCC cell lines
were treated with 5-Aza-dC in conjunction with the
TSA. Our result showed that MAL gene transcription
was reactivated in 67% (6/9) of the HNSCC cell lines
after treatment with 5-Aza-dC, while 89% (8/9) of the
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neous treatment with 5-Aza-dC and TSA. In addition,
the levels of MAL mRNA increased in 44% (4/9) of
HNSCC cell lines treated with TSA alone as compared
to the untreated control (Figure 3A). To further explore
the epigenetic mechanism, the putative CpG islands
around MAL transcriptional start site (TSS) were
screened by using bioinformatics tools. Two major CpG
islands M1 (distance to TSS, -626 to -385 bp) and M2
(distance to TSS, +390 to +669 bp) were found. Next, to
evaluate the methylation status of the two major CpG
islands around the MAL TSS, bisulfate-treated DNA
sequencing was performed in two randomly selected
HNSCC cell lines and seven pairs of HNSCCs from 48
cases. The results demonstrated that both CpG islands
(that is, M1 and M2) were completely methylated in the
HNSCC cell lines (CpG methylated ratio more than
90%) relative to normal primary head and neck epithe-
lial cells (P < 0.01). However, the methylation level of
the CpG island (that is, M1) in the MAL putative pro-
moter but not the CpG island in the intragenic regions
(that is, M2) was significantly higher in all seven
HNSCC cases than in the corresponding adjacent non-
cancerous tissues (P < 0.01, Figure 3B, 3C)
MAL inhibits cell proliferation and colony formation, thus
inducing G1-phase arrest
To evaluate whether MAL functions as a tumor suppres-
sor in HNSCC cells, we assessed the effect of MAL
expression on cell proliferation and colony formation.
Based on the MAL expression pattern in HNSCC-derived
cell lines (Figure 2C), we transiently transfected mamma-
lian expression vectors containing MAL into Tca, Tca-M
and Tb cells, all of which lacked endogenous MAL
expression. MAL over-expression suppressed the growth
and colony formation ability of these cells relative to
mock-transfected controls (P < 0.01, Figure 4A and 4B).
To validate which cell population was altered most
remarkably in cell cycle distribution, flow cytometry was
performed in randomly selected cell line. Our results
showed that the MAL-transfected cells had a marked
increase in the number of cells in the G1-phase as
Figure 1 Identification of MAL gene splicing isoforms in oral squamous epithelium. (A) Structure of the human MAL gene and PCR primers
used to determine expression of MAL variants. The MAL gene has four exons and encodes four major transcripts, namely, full-length isoform a
and isoform b which lacks exon 3, isoform c which lacks exon 2, and isoform d which lacks exon 2 and exon 3. Primers MAL-98F and MAL-472R
were used to discriminate four variants, namely, a, b, c, and d. (B) Expression of alternatively spliced MAL isoforms in 10 cases of normal oral
squamous epithelium using semi-quantitative RT-PCR analysis. b-actin was amplified as a control.
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vs. 59.61% ± 6%, P < 0.05, Figure 4C.) This indicates that
the cells expressing exogenous MAL become blocked at
the G1/S transition.
Induction of apoptosis in HNSCC cells by ectopic MAL
expression
To determine whether the inhibitory effect of MAL expres-
sion on cells was caused by apoptosis, two independent
assays were performed. As shown in Figure 5A, MAL
expression induced an increase in the number of sub-G1
cells. After 24 hours, 48 hours and 72 hours of transient
transfection, the apoptotic rates of the MAL-transfected
Tca cells were 1.14%, 4.04%, and 11.71%, respectively, as
compared with 1.07%, 2.20%, and 4.01%, respectively, for
the control cells (48 hours and 72 hours, P < 0.01). In addi-
tion, we assessed the fraction of cells with positive staining
for 7-amino-actinomycin (7-AAD) and Annexin V-PE in
MAL-transfected Tca cells (7.54%) and the control cells
(2.60%) (Figure 5B). Furthermore, we also examined the
Figure 2 MAL mRNA expression in HNSCC specimens and HNSCC cell lines. (A) Representative results of gel electrophoresis from 24 pairs
of HNSCC(C) and their adjacent normal oral epithelium (N). (B) Real-time RT-PCR analysis of MAL was carried out in 48 pairs of HNSCC and
adjacent normal oral epithelium. For each sample, the relative mRNA level of MAL was normalized to b-actin. The line within each box
represents the median Ct value; the upper and lower edges of each box represent the 75
th and 25
th percentiles, respectively; the upper and
lower bars indicate the highest and lowest values determined, respectively. (C) Expression of MAL mRNA in nine representative HNSCC cell lines
and human immortalized oral epithelial cells (HIOEC) using semi-quantitative RT-PCR analysis with normal human oral epithelial cell (NHOEC) as a
positive control (POS.) and no cDNA template as a negative control (NEG.).
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cleavage, which is a hallmark of apoptosis [25], using Wes-
tern blot analysis after transient transfection with an empty
vector or MAL at 48 hours, 72 hours (Figure 5C).
Effect of exogenous MAL expression suppresses invasion
of HNSCC cell line
In vitro invasion assays were performed to determine the
effect of MAL on cell invasion using BD BioCoat™Matrige-
l™Invasion Chambers. The Matrigel™matrix served as a
reconstituted basement membrane in vitro.A ss h o w ni n
Figure 6A and 6B, the number of cells that invaded through
the transwell membrane in clone #12, which expresses
MAL (65 ± 32), was significantly lower than those in clone
#6, which does not express MAL (178 ± 44, P <0 . 0 1 ) .
Ectopic expression of MAL reduces tumor growth in
nude mice
Since MAL expression represses the malignant properties
of HNSCC cells in vitro, we also evaluated the effect of
Figure 3 7Aberrant methylation of promoter region mediated the silencing of MAL in HNSCC. (A) Pharmacogenetic treatment of nine
HNSCC cell lines with or without 5-Aza-dC and/or TSA. Primary keratinocytes were used as the positive control (POS.), and no template added in
the PCR reaction was regarded as the negative control (NEG.). (B) Schematic representations of the location of the CpG islands within the
promoter and the intragenic regions of MAL and the location of the bisulfate-based sequencing within the CpG island. (C) Representative results
from the bisulfate-treated genomic DNA sequencing to detect the methylation status of the BS-1 and BS-2 regions in two representative HNSCC
cell lines and seven HNSCCs as compared with the methylation level in primary keratinocytes and matched normal epithelium cells (P < 0.05).
The numbers indicate the CG dinucleotide within the CpG island in the promoter. Black and white circles represent methylated and
unmethylated CpGs, respectively.
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purpose, Tca cells expressing MAL (clone #12) and cells
not expressing MAL (clone #6) were injected subcuta-
neously into the left and right posterior limb of nude
mice, respectively. After four weeks, the animals were exe-
cuted, and the tumor weights were measured. The results
showed that tumor growth was significantly reduced in
MAL-expressing (clone #12) cells as compared to MAL-
non-expressing (clone #6) cells (P < 0.05, Figure 6C).
Discussion
Several research groups have recently extensively inves-
tigated the transcriptome and proteome of HNSCCs
using high-throughput microarray technology [26-29].
The aims were to identify genes that were potentially
involved in HNSCC progression and to find diagnostic
and prognostic gene expression signatures. These mole-
cular signatures could provide key clues to early diagno-
sis; they could also guide prognosis and the design and
Figure 4 Effect of MAL on cell growth and colony formation of HNSCC cell lines. (A) Exogenous MAL expressed in Tca, Tca-M and Tb cells
transfected with the pcDNA3.1 vector. Parental cells with empty vector were used as a control. The growth of these cells was analyzed using
the CCK-8 kit, and the symbols represent the mean values of triplicate tests (mean ± SD). Western blot analysis indicated the expression of MAL
in these cell lines. A t-test was used to show significant differences between the two groups (P < 0.05). (B) To examine the effect of MAL on
colony formation, pcDNA3.1-MAL was transfected into these three cell lines. After transient transfection for 24 hours, the cells were harvested
and seeded onto 100 mm dishes and cultured in G418 for 14 days. The representative dishes show the inhibitory effect of MAL on colony
formation, and the lower graphics show that colony formation was significantly suppressed by MAL as compared with the empty vector control
(P < 0.05). All experiments were repeated at least three times. (C) The cell cycle distribution after transient transfection with pcDNA3.1-MAL or an
empty vector as assessed by flow cytometry.
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previous study using cDNA microarray analysis, we
identified MAL as a remarkably down-regulated gene in
HNSCCs as compared with adjacent normal tissues.
Furthermore, Lallemant et al [31] reviewed 23 papers
published between March 2000 and November 2007 to
find that the MAL gene was down-regulated in
HNSCCs, which is consistent with our microarray data.
Thus, we hypothesized that the MAL gene could be a
candidate HNSCC-specific molecular marker. However,
although MAL has been implicated in the overall apical
delivery of secretory proteins and transmembrane pro-
teins [32,33], the role of MAL in HNSCC progression
has not been addressed yet. In this study, our data
demonstrated a close correlation of MAL expression
with carcinogenesis and/or progression of human
HNSCC (Figure 2).
The genetic and epigenetic silencing of tumor sup-
pressor genes is considered a vital molecular event in
the development and progression of HNSCC [34].
Although MAL is located at chromosome 2q13, a region
that is involved in large homozygous deletions in juve-
nile nephronophthisis [35], no deletions or mutations
have been reported yet with respect to human cancer.
However, the previous studies indicated that DNA
methylation level of MAL promoter was increased in
various types of carcinoma [9,36-38]. Moreover, the
induction of MAL gene expression by DAC or TSA was
described by some studies [8,9,11]. Furthermore, in
addition to hypermethylation of MAL gene promoter in
9(45%) out of 20 HNSCC cell lines, Beder et al showed
that loss of heterozygosity (LOH) still occur in 9 (30%)
of 29 primary HNSCCs [21]. Considering these findings,
here we hypothesized that MAL was inactivated in
Figure 5 Effect of MAL on HNSCC cell apoptosis. (A) Sub-G1 apoptotic cells induced by ectopic expression of MAL in Tca cells transfected
with pcDNA3.1-MAL vector were analyzed using PI staining and flow cytometry at different time points. Parental cells with an empty vector
were used as a control. The lower histogram shows that exogenous MAL markedly induced apoptosis after transient transfection for 48 hours as
compared with the control vector (P < 0.01). (B) To further observe the effect of MAL on cell apoptosis, after transient transfection for 72 hours,
the cells were harvested and stained with 7-AAD and Annexin V-PE and then analyzed using flow cytometry. (C) Expression of cleaved PARP was
assessed by Western blotting after transient transfection with pcDNA3.1-MAL and the empty vector for 48 hours and 72 hours.
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ifications, although not exclude the possibility that the
gene dosage of MAL such as LOH affects its expression.
To evaluate effect of the DNA methylation and his-
tone acetylation status on MAL expression in HNSCC
cell lines, in this study, we used pharmacological treat-
ment on these cells with the demethylation agent DAC
in conjunction with (and without) the histone deacety-
lase inhibitor TSA. Consistent with above findings, our
results showed that the MAL gene was reactivated in
most HNSCC cell lines (Figure 3A), suggesting that
DNA promoter methylation and histone deacetylation as
major factors were involved in silencing the MAL gene.
Although MAL gene hypermethylation in HNSCC cell
lines was found by Beder et al [21], more detailed DNA
hypermethylation status within MAL gene promoter in
HNSCC cells, especially in paired HNSCCs and corre-
sponding normal tissues should be further evaluated.
Moreover, the correlation between MAL transcriptional
level and DNA methylation status in these HNSCC spe-
cimens needs to be elucidated. To address these issues,
we first used bioinformatics tools to determine whether
t h e r ew e r eC p Gi s l a n d si nt he regulatory elements of
the MAL gene from 2,000 bp upstream to 200 bp down-
stream of the transcription start site. In addition, we
also examined the sequences of the intragenic regions.
Interestingly, two major CpG islands were identified.
They were located at upstream region, -626 bp to -385
bp (M1, including 22 CpG sites) and downstream
region, +390 bp to +669 bp (M2, including 20 CpG
sites) of MAL TSS (Figure 3B), respectively. It should be
pointed out that these CpG islands have never been
Figure 6 The effect of MAL on cell invasion and tumorigenicity. (A) The representative picture shows that stable cells expressing MAL were
selected according to Western blotting after the single-cell cluster was cultured in 600 μg/ml of G418 for four weeks, and the stable cells #12
with exogenous expression of MAL were further validated by immunofluorescence as indicated in the lower graphic. (B) Cell invasion of clone
#6 and #12 were evaluated with a Matrigel assay. Cell counts represent mean values per field from five fields over three independent
experiments (lower) (mean ± SD). (C) Increased ectopic MAL expression inhibited xenograft tumor growth of Tca stable cells #12 relative to Tca
stable cells #6 that do not express MAL. These cells were injected subcutaneously into nude mice, and tumors were excised after four weeks.
Tumors weights were measured (mean ± SD.), and MAL expression in tumors was assessed using Western blotting.
Cao et al. Molecular Cancer 2010, 9:296
http://www.molecular-cancer.com/content/9/1/296
Page 8 of 13included in other studies in various cancers [9-11,36,37].
In this study, we employed bisulfate-treated DNA
sequencing to measure promoter hypermethylation,
which allows for an objective, robust, and global assess-
ment of promoter methylation status as compared with
methylation-specific PCR. Our data indicated that both
CpG islands (M1 and M2) around the MAL TSS were
completely methylated in HNSCC cell lines relative to
normal primary head and neck epithelium cells (P <
0.01). Only the methylation level of the first CpG island
(that is, M1) in the MAL promoter was significantly
higher in all seven HNSCC cases as compared to the
corresponding adjacent noncancerous tissues (P <0 . 0 1 ) ,
suggesting M1 is a major hypermethylated region
around TSS of MAL gene in HNSCC. Accordingly,
MAL transcript levels were decreased in all seven
HNSCC cases as compared to the corresponding adja-
cent noncancerous tissues. Based these data and findings
in other cancers, we proposed that DNA hypermethyla-
tion of the MAL regulatory elements could be a major
contributor to the downregulation of MAL in HNSCC.
However, it should be emphasized that, in addition to
DNA hypermethylation, histone modification such as
deacetylation status also affected MAL expression in
HNSCC. Further study on this issue would provide the
novel insight to elucidate the mechanism by which both
DNA methylation and histone deacetylation play a
synergic role in silencing of MAL gene.
MAL was first postulated as tumor suppressor protein
by Mimori et al [8]. The reactivated expression of MAL
gene exerts an inhibitory effect on motility and tumori-
genicity of esophageal cancer. Moreover, MAL can
induce apoptosis of cancer cells. However, the effect of
MAL on HNSCC cells was unclear, due to the lack of
in vitro and in vivo functional experiments for MAL gene
in HNSCC. Considering the particularity of HNSCC in
epidemiology which is remarkably different from other
cancer types, as well as the distinct molecule signatures
in initiation and progression, in the present work, we
evaluated the functional role of MAL gene in three
HNSCC cell lines in order to determinate whether MAL
might be as a therapeutic target for HNSCC. Our experi-
mental results showed that MAL gene overexpression
could exert strong antiproliferative effects on HNSCC
cells by blocking cells at the G1/S transition. Further-
more, the Annexin V-PE and 7-AAD staining, along with
the increasing cell population in sub-G1 phase and ele-
vating cleaved PARP level revealed that the inhibitory
effect of MAL on cell proliferation was through inten-
sively inducing early apoptosis of cancer cells. Accord-
ingly, our results also demonstrated that exogenous
expression of MAL could suppress the invasive ability
and tumorigenicity of HNSCC cells, which was consistent
with the findings described in esophageal cancer.
Conclusion
Our study shows that MAL inactivation is functionally
involved in HNSCC progression and that the MAL gene
promoter is hypermethylated, which is a predictor of the
reduced MAL mRNA expression levels in both HNSCC
tissues and cell lines. As such, our study strongly sug-
gests that the MAL gene may be a candidate tumor sup-
pressor in HNSCC and a potential and novel
therapeutic target for HNSCC.
Methods
Carcinomas and control specimens
The samples were collected at the Department of Oral and
Maxillofacial Surgery at the Affiliated Ninth People’s Hos-
pital of Shanghai Jiao Tong University School of Medicine
from 2000 to 2009. All samples were obtained by surgery
and then quickly frozen in liquid nitrogen until DNA and
total RNA were extracted. Normal tissues adjacent to the
tumors were also obtained with the patient’sc o n s e n t .
Tumors were classified histologically and staged according
to the tumor-node-metastasis (TNM) classification of
malignant tumors [39]. Tumor pathological grade was
assessed according to standard criteria [40].
Cell lines
The human cell lines Tca8113 (Tca), Tca8113-M
(Tca-M), Tb, Tca/CDDP (established in the Ninth Peo-
ple’s Hospital, Shanghai Jiao Tong University School of
Medicine), TSCC (kindly provided by Wuhan University,
School of Dentistry, China), OSC-4 (kindly provided by
Kochi University, School of Medicine, Japan), NB and
NT (kindly provided by Nagasaki University School of
Dentistry, Japan) were cultured in RPMI-1640 medium
(GIBCO BRL, USA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; GIBCO BRL, NY,
USA), penicillin (100 units/ml) and streptomycin (100
μg / m l )a t3 7 ° Ci nah u m i d i f i e d5 %C O 2a t m o s p h e r e .
CAL-27 (American Type Culture Collection, Manassas,
VA, USA) was cultured in Dulbecco’sm o d i f i e dE a g l e
medium (DMEM; GIBCO BRL, USA) supplemented with
10% heat-inactivated FBS), penicillin (100 units/ml) and
streptomycin (100 μg/ml) at 37°C in a humidified 5%
CO2 atmosphere. The immortalized oral keratinocyte
line HIOEC from primary normal human oral epithelial
cells infected with HPV16E6E7 (established in the Ninth
People’s Hospital, Shanghai Jiao Tong University School
of Medicine) was cultured in a defined keratinocyte
serum-free medium (KSFM; GIBCO BRL, USA).
RNA preparation in semi-quantitive reverse transcription-
polymerase chain reaction (RT-PCR) analysis
Total RNA was extracted from each tissue sample and
cell line using the TRIZOL reagent (Invitrogen, San
Diego, USA). The quality of the total RNA samples was
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ose gels, and the 18 S and 28 S RNA bands were visua-
lized under ultraviolet light. Then 2 μgo ft o t a lR N Aw a s
reverse-transcribed directly to cDNA using a reverse
transcription kit (Promega, Madison, USA) following the
manufacturer’s instructions in a total volume of 25 μl.
The primer sequences used were as follows: MAL for-
ward, 5’-CAGTGGCTTCTCGGTCTT-3’; MAL reverse,
5’-AGCAGAGTGGCTATGTAGGA-3’; b-actin forward,
5’-TCACCCACACTGTGCCCATCTACGA-3’;a n db-
actin reverse, 5’-CAGCGGAACCGCTCATTGC-
CAATGG-3’; Each primer was added at a final concen-
tration of 0.5 μMt oa1 5μl reaction mixture in PCR
buffer containing 1 μl of cDNA, 0.25 mM of each dNTP,
1.5 mM of MgCl2, and 2.5 units of Taq DNA polymerase.
An initial denaturation was carried out for 5 minutes at
94°C, and 35 cycles were performed with the following
PCR program: denaturing at 94°C for 30 seconds, anneal-
ing at 45-60°C for 30 seconds for MAL and 55°C for
30 seconds for b-actin, and elongation at 72°C for 30 sec-
onds. This program was completed with a final extension
at 72°C for 5 minutes. Ethidium bromide-stained bands
were visualized using UV transillumination, and fluores-
cence intensity was quantified using the FR-200 system
(FuRi, Shanghai, China). The data from semi-quantitive
PCR reactions were normalized against the expression of
b-actin from three independent experiments ± the stan-
dard deviation (SD). All RT-PCR data were from at least
three independent experiments.
Real-time PCR
All real-time PCR reactions were performed using a
Thermal Cycler Dice™Real Time System (Takara) and the
SYBR Premix Ex Taq™reagents kit (Takara, Japan). The
real-time PCR was performed in a final volume of 15 μl
with 1.5 μl of template cDNA at a concentration of
20 ng/μlw i t h7 . 5μl SYBR green I fluorescent dye and
20 pM of each primer for the target gene and the house
keeping gene (b-actin). The primer sequences included
sense 5’-GGGCTGGGTGATGTTCGT-3’ and anti-sense
5’-TAGGCTGCGTCCAAGGTG-3’ for MAL (117 bp)
and sense 5’-CCTGGCACCCAGCACAAT-3’ and anti-
sense 5’-GGGCCGGACTCGTCATACT-3’ for b-actin.
Results of real-time PCR were represented as Ct values,
where Ct was a fraction defined as the cycle number at
which the sample fluorescent signal passes a given
threshold above the baseline. ΔCt was the difference in
the Ct values derived from the specific genes after being
assayed and b-actin. The N-fold differential expression in
a specific gene of a tumor sample, matched normal tissue
and cell lines were expressed as 2
ΔCt [17]. The signifi-
cance level was defined as a P-value of less than 0.01.
Induction of gene expression by 5-Aza-dC, TSA and
5-Aza-dC in combination with TSA
To induce demethylation of promoter prior to evaluation
for induction of MAL expression, all of the above-
mentioned HNSCC cell lines were treated with 2 μM
5-Aza-dC, which is the DNA demethylation reagent, for
72 hours, 0.5 μM TSA, which is a specific inhibitor of
histone deacetylase, for 24 hours, or 2 μM 5-Aza-dC for
72 hours plus 0.5 μM TSA for 24 hours.
Direct bisulfate sequencing
Genomic DNA was treated with bisulfate as previously
described [18]. Briefly, 1 μg genomic DNA was denatured
by incubation with 0.2 M NaOH. Aliquots of 10 mM
hydroquinone and 3 M sodium bisulfate (pH = 5.0) were
added, and the solution was incubated at 50°C for 16
hours. To analyze the DNA methylation status of the CpG
islands of MAL promoter in HNSCCs and cell lines,
regions enriched in CpG islands were amplified in bisul-
fate-treated genomic DNA using the primers CpG island
I, forward, 5’-GGAGTAATTTTTTATTTTTAGGTAGA-
3’; reverse, 5’-AAATTTAAATCTCCTTCATTTTTCC-3’;
CpG island II, forward, 5’-TTTAATTGGGGTTAGATG-
TAGGTAG-3’;a n dr e v e r s e ,5 ’-AAAAACTTTAAAAAAC-
CAAAAAAAA-3’. The PCR products were then
subcloned into a pMD18-T vector (TaKaRa Inc. Japan) for
DNA sequencing on an ABI 3730 sequencer.
Western blotting
The cells were washed with PBS twice and lysed for 30
minutes in 25 mM Tris-HCl with a pH of 7.5 and con-
taining 150 mM NaCl, 5 mM EDTA, and 1% Triton
X-100 at 4°C. The lysate was homogenized by passing
the sample through a 22-gauge needle. The glycolipid-
enriched membrane (GEM) was isolated from the lysate
by equilibrium centrifugation for Western blot analysis
with an anti-c-myc monoclonal antibody (mAb). In
brief, for immunoblot analysis, the GEM samples were
run on SDS-PAGE in 12% acrylamide gels and trans-
ferred onto nitrocellulose membranes (Amersham, NA,
England). After blocking with 5% nonfat dry milk and
0.05% Tween-20 in PBS, blots were incubated with anti-
c-myc mAb (Santa Cruz Biotechnology, CA, USA), anti-
cleavage PARP polyclonal antibody (Cell signaling, MA,
USA) and anti-b-actin mAb (Sigma, St Louis, MO,
USA) at the optimized dilutions. Bands were detected
using an IRDye™800 Conjugated Affinity Purified Anti-
Mouse IgM antibody (Rockland, Gilbertsville, PA, USA).
The membrane was then washed several times and
scanned using the Odyssey infrared imaging system (LI-
COR, Lincoln, NE, USA) at an 800 channel wavelength
and analyzed with Odyssey software.
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transfection of constructs
To generate the MAL expression vector, the open read-
ing frame of human MAL cDNA was cloned into the
eukaryotic expression vector pcDNA3.1 (Invitrogen, San
Diego, CA, USA) and fused to a COOH-terminal Myc
tag. The primers used for the amplification of the open-
reading frame of the MAL cDNA were GCGAATTCAC-
CATGGCCCCCGCAGCGGCGACG (forward primer),
with an EcoRI site, and GCAAGCTTGCTGAA-
GACTTCCATCTGATTAAAG (reverse primer), with a
HindIII site without the stop codon. The amplified MAL
gene product was purified using a Qiaquick PCR Purifi-
cation Kit (Qiagen, Chatsworth, CA, USA), cut with
EcoRI and HindIII and ligated with the Ligation Mix
(TakaRa, Dalian, China) into the respective EcoRI and
HindIII sites on the eukaryotic expression vector
pcDNA3.1. For transient transfection, the cells were
transfected with various plasmids at about 80% conflu-
ence using the Lipofectamine™2000 (Invitrogen, San
Diego, CA, USA) reagent according to the manufac-
turer’s instructions. To generate stable MAL-expressing
cell lines, cells were selected with G418 (600 μg/ml) for
two weeks, and drug-resistant cells were screened using
Western blot analysis with the anti-human c-myc mAb
to detect MAL-myc. The clones that exhibited positive
immunoreactivity were maintained in G418 (300 μg/ml)
medium. Mock-transfected, MAL-transfected (but not
MAL-expressing) and MAL-expressing stable cells were
denoted as 3.1-vector, clone #6, and clone #12,
respectively.
Cell-proliferation assay
Cell-proliferation assay was performed to analyze the
proliferation potential of transiently transfected empty
vector and MAL-transfected cells. To this end, we used
the Cell-Counting Kit (CCK)-8 (Dojindo, Kumamoto,
Japan). Briefly, the cells were harvested and plated in
96-well plates at 1 × 10
3 cells per well and maintained
at 37°C in a humidified incubator. At the indicated time
points, 10 μl of the CCK-8 solution was added into the
triplicate wells and incubated for 1 hour, and the absor-
bance at 450 nm was measured to calculate the number
of vital cells in each well. Measurements were per-
formed in triplicate, and the Mean (±SD) optical density
(OD) was reported.
Colony Formation assay
Twenty-four hours after transfection, the cells (1 × 10
5
cells per plate) were plated in 100-mm culture dishes
and incubated with 600 μg/ml of G418 for 14 days to
allow for colony formation. The colonies were then
washed twice with PBS, fixed with 70% ethanol and
stained with 0.1% Coomassie Brilliant Blue R-250.
Colonies of more than 50 cells were counted under a
dissecting microscope. The data from colony formation
were shown as means (± SD) from at least three inde-
pendent experiments, each performed in triplicate.
Cell cycle distribution assay
Empty vector and MAL-transfected cells at the logarith-
mic growth phase were harvested, and single-cell sus-
pensions containing 1 × 10
6 cells were permeabilized
with 70% ethanol. The cells were then labeled with
50 μg/ml of propidium iodide (PI) and treated with
250 μg/ml of RNase at 4°C for 30 minutes. Analysis was
performed using FACS Calibur (BD Biosciences, San
Jose, CA, USA) and analyzed using Cell Quest Software
( B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A ) .T h ed a t ar e p r e -
s e n tt h eM e a n s( ±S D )f r o ma tl e a s tt h r e ei n d e p e n d e n t
experiments.
Apoptosis assay
The cells were harvested 24 hours, 48 hours, and
72 hours after transient transfection. Then they were
washed once in PBS, permeabilized with 70% ethanol
for 20 minutes and stored at -20°C overnight. The cells
were then subsequently washed with PBS and stained
with 50 μg/ml of propidium iodide at 4°C for 30 min-
utes. Apoptotic cells were assessed by flow cytometry
for sub-G1 DNA content. Meanwhile, apoptosis was
assessed using Annexin V-PE staining 72 hours after
transfection. Then, these cells were quantified by flow
cytometry using the Annexin V-PE Apoptosis Detection
Kit (BD Biosciences, San Jose, CA, USA) according to
the manufacture’s protocols. Briefly, floating cells and
trypsinized adherent cells were pooled and resuspended
in 100 μl of Annexin V-PE Binding Buffer. Then 5 μlo f
Annexin V-PE and 5 μl of 7-AAD were added, and the
cells were incubated for 15 minutes at 25°C. The cells
were then resuspended in 400 μlo ft h eA n n e x i nV - P E
binding buffer and analyzed immediately by flow cyto-
metry. Then 10,000 events were scored by the FACSCa-
libur and analyzed using the Cell Quest software.
Confocal microscope
Stable cells, that is, clone #6 and clone #12, were grown
on coverslips and washed once with ice-cold PBS and
fixed for 30 minutes in 4% paraformaldehyde at 4°C. For
immunostaining, the fixed cells were permeabilized with
0.1% Triton X-100 in PBS for 5 minutes, washed and
blocked with PBS containing 0.05% Tween-20 and 5%
horse serum (HS) for 30 minutes at room temperature,
and incubated with a 1:500 dilution of anti-c-myc mAb
in PBS supplemented with 0.05% Tween-20 and 5% HS
in a humidified chamber at 4°C overnight. The cells
were then rinsed three times with 0.05% Tween-20 in
PBS and incubated with a 1:100 dilution of secondary
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in PBS. The cells were then rinsed three times with
0.05% Tween-20 in PBS. All fluid was then removed,
and two separate drops of Gel Mount-4’ and 6’ dia-
mino-2-phenylindole·2HCl (DAPI) were applied to the
sections. A cover slip was then carefully lowered onto
the sections. The cells were then imaged using a TCS-
SP laser-scanning confocal microscope with a ×40 oil
immersion lens (Leica Microsystems, Mannheim,
Germany).
Cell invasion assay
In vitro invasion assay was performed to analyze the
invasive potential of stable clone #6 and clone #12 cells.
A total of 1 × 10
5 cells in 750 μlo fs e r u m - f r e eR P M I -
1640 medium were plated onto BD BioCoat ™Matrigel
™Invasion Chambers (8 μm pore size; BD Biosciences,
USA) with the lower chamber containing 750 μlo f
RPMI-1640 medium with 10% FBS as a chemoattrac-
tant. After 48 hours of incubation in a humidified atmo-
sphere containing 5% CO2 at 37°C, the non-invading
cells were removed from the upper surface of the mem-
brane by a cotton swab. The membranes were then
fixed with methanol and stained with 0.5% crystal violet
stain. Invading cells were photographed and counted in
five random non-overlapping 200× fields under a light
microscope.
Tumorigenicity in vivo
Nude mice (4-6 weeks old) were used for xenograft stu-
dies. Tca cells (1.5 × 10
6 in PBS) expressing MAL (clone
#12) or not (clone #6) were injected subcutaneously in
the extremities of the nude mice. After four weeks,
nude mice bearing tumors were executed, and tumor
weight was measured using an electronic balance. The
values for nine mice in each group were averaged to
obtain the mean ± (SD) Differences in tumor weights
were analyzed using the Student’s t-test.
Statistical analysis
Semi-quantitative RT-PCR, real-time PCR and in vitro
statistical analyses were performed with software from
SPSS 13.0 for Windows (Chicago, IL, USA). Results of
the semi-quantitative RT-PCR and real-time PCR ana-
lyses were evaluated using the Mann-Whitney test for
two independent groups. The results of the cell prolifera-
tion assay, colony formation assay, and in vitro invasion
assay were evaluated using Student’s t-tests. A P-value of
less than 0.05 was considered significant.
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